The antioxidant anethole dithiolethione inhibits monoamine oxidase-B but not monoamine oxidase A activity in extracts of cultured astrocytes.
Anethole dithiolethione (ADT) is a clinically available, pluripotent antioxidant proposed as a neuroprotectant for Parkinson's disease (PD). Here, using extracts from cultured astrocytes, containing both monoamine oxidase (MAO) A and B activity, we demonstrate that ADT concentration-dependently inhibits MAO-B activity in a clinically relevant concentration range (0.03-30 microM, IC-50 = 0.5 microM) without affecting MAO A activity. Considering the alleged contribution of MAO activity in general, and MAO-B in particular, to oxidative stress and neurodegeneration in PD, our data further support the neuroprotective potential of ADT.
Drukarch
B
B
Department of Medical Pharmacology, Research Institute Neurosciences Vrije Universiteit, VU University Medical Center, Amsterdam, The Netherlands. b.drukarch@vumc.nl
Flier
J
J
Jongenelen
C A M
CA
Andringa
G
G
Schoffelmeer
A N M
AN
D000704:Analysis of Variance; D000781:Anethole Trithione / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000494:pharmacology*; D001253:Astrocytes / Q000187:drug effects*; D001479:Basal Ganglia / Q000166:cytology; D002478:Cells, Cultured; D003010:Clorgyline / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D051381:Rats
D000975:Antioxidants; D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase; D003010:Clorgyline; D000781:Anethole Trithione